Melbourne (Australia) – 15 October 2018. Telix Pharmaceuticals Limited announced an extension to its master service agreement (MSA) with Cyclotek (Aust) Pty Ltd to include 89Zr-Girentuximab (TLX250-CDx) for imaging patients with clear cell renal cell cancer (ccRCC) using Positron Emission Tomography (PET). The full media release can be accessed here.